Synapse - Works

Results (5608)

Single-cell multiplex immunofluorescence of formalin-fixed, paraffin-embedded prostate cancer tissue identifies PI3K pathway activation in two prospective cohort studies

Meeting Abstract

Stopsack, K. H.; Huang, Y.; Tyekucheva, S.; Gerke, T. A.; Bango, C.; Elfandy, H.; Gao, X.; Cai, Z.; Roberts, T. M.; Kantoff, P. W.; more...
Molecular Cancer Research (2020)

Fulltext@MSK | Save

AKT mutant allele-specific activation dictates pharmacologic sensitivities

Meeting Abstract

Shrestha Bhattarai, T.; Shamu, T.; Patel, S.; Gorelick, A.; Chang, M. T.; Gavrila, E. I.; Gao, J. J.; Donoghue, M. T. A.; Gao, P. S.; Soumerai, T.; more...
Molecular Cancer Research (2020)

Fulltext@MSK | Save

Diagnostic performance of PSMA-targeted (18)F-DCFPyL PET/CT in men with biochemically recurrent prostate cancer: Results from the phase 3, multicenter CONDOR study

Meeting Abstract

Rowe, S.; Gorin, M.; Saperstein, L.; Pouliot, F.; Josephson, D.; Carroll, P.; Wong, J.; Pantel, A.; Piert, M.; Gage, K.; more...
Journal of Nuclear Medicine (2020)

Fulltext@MSK | Save

Delta-like ligand 3 (DLL3) is a novel target for molecular imaging of neuroendocrine prostate cancer

Meeting Abstract

Korsen, J.; Kalidindi, T.; Khitrov, S.; Khuram, H.; Piorier, J.; Rudin, C.; Chen, Y.; Pillarsetty, N. V. K.; Lewis, J.
Journal of Nuclear Medicine (2020)

Fulltext@MSK | Save

Implementation of Symptom Care Clinic (SCC) for acute symptoms management at outpatient oncology ambulatory centers

Meeting Abstract

Xiao, H.; Fahy, R.; Salvaggio, R.; OSullivan, M.; Sokoli, D.; Murray, C.; Majeed, J.; Mao, J. J.; Groeger, J. S.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

CD68+ tumor-associated myeloid cells as the target of adenosine-induced gene products and predictor of response to adenosine blockade with ciforadenant (cifo) in renal cell cancer (RCC)

Meeting Abstract

Voss, M. H.; Hotson, A. N.; Willingham, S.; Hughes, B. G. M.; Merchan, J. R.; Fong, L.; Chu, M.; George, S.; Munneke, B.; Mobasher, M.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)

Meeting Abstract

Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi)

Meeting Abstract

Schonhoft, J.; Gill, A.; Graf, R. P.; Jendrisak, A.; Barnett, E.; Benoliel, H.; Carbone, E.; Tubbs, A.; Orr, S.; Byun, J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane

Meeting Abstract

Scher, H. I.; Jendrisak, A.; Gill, A.; Barnett, E.; Gopalan, A.; Zaidi, S.; Benoliel, H.; Carbone, E.; Byun, J.; Schonhoft, J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Rosenberg, J. E.; Flaig, T. W.; Friedlander, T. W.; Milowsky, M. I.; Srinivas, S.; Petrylak, D. P.; Merchan, J. R.; Bilen, M. A.; Carret, A. S.; Yuan, N.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save